

## Special Issue

# Drug Delivery Systems for Treatment of Leishmaniasis

### Message from the Guest Editors

*Leishmania* is a protozoan responsible for leishmaniasis, a disease that is transmitted to vertebrate hosts through the bite of female sand flies. This parasite has a dimorphic life cycle, consisting of intracellular amastigote and free promastigote forms. The amastigote multiplies in the cytoplasm of macrophages of vertebrate hosts causing the clinical effects of leishmaniasis. Leishmaniasis is classified as cutaneous, mucocutaneous or visceral depending on the tissues infected. Despite its severity and increasing diffusion, no efficient therapy with low toxicity and side effects is currently available. Alternative and innovative treatments such as local and self-administering therapies, treatments combining several drugs and different administration routes, and drug repurposing through new nanotechnological delivery systems are needed to overcome these drawbacks. We are pleased to invite you to submit your work related to (new) drugs against leishmaniasis and/or different strategies to administer them. Original research articles and reviews are welcome.

---

### Guest Editors

Prof. Dr. Xavier Fernàndez-Busquets

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, Planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

Dr. Yunuen Avalos-Padilla

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, Planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/138251](https://mdpi.com/si/138251)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).